Skip to main content
. 2018 Feb 27;23(6):686–692. doi: 10.1634/theoncologist.2017-0578

Figure 2.

image

Overall survival (OS) by concomitant pH‐elevating medication. OS was 28 months in the PPI/H2RA group (95% confidence interval [CI] 19.0–41.0) versus 30.1 months in the no PPI/H2RA group (95% CI 17.0–47.0); p = .92 by log‐rank test, adjusted hazard ratio 0.99 (95% CI 0.51–1.93) by Cox regression.

Abbreviations: H2RA, histamine 2 receptor antagonist; PPI, proton pump inhibitor.